Haleos Labs Limited
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, a… Read more
Haleos Labs Limited (HALEOSLABS) - Total Liabilities
Latest total liabilities as of September 2025: ₹1.71 Billion INR
Based on the latest financial reports, Haleos Labs Limited (HALEOSLABS) has total liabilities worth ₹1.71 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Haleos Labs Limited - Total Liabilities Trend (2017–2025)
This chart illustrates how Haleos Labs Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Haleos Labs Limited Competitors by Total Liabilities
The table below lists competitors of Haleos Labs Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CHYYY
PINK:CHYYY
|
USA | $9.37 Trillion |
|
GRK Infra
HE:GRK
|
Finland | €304.74 Million |
|
KYOCERA (KYR.SG)
STU:KYR
|
Germany | €1.21 Trillion |
|
Kayne Anderson BDC, Inc.
NYSE:KBDC
|
USA | $1.18 Billion |
|
DT REAL ESTATE (DRE2.SG)
STU:DRE2
|
Germany | €115.56 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Haleos Labs Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Haleos Labs Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Haleos Labs Limited (2017–2025)
The table below shows the annual total liabilities of Haleos Labs Limited from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹1.78 Billion | -9.99% |
| 2024-03-31 | ₹1.98 Billion | -4.35% |
| 2023-03-31 | ₹2.07 Billion | +7.74% |
| 2022-03-31 | ₹1.92 Billion | +8.88% |
| 2021-03-31 | ₹1.76 Billion | +25.87% |
| 2020-03-31 | ₹1.40 Billion | -15.63% |
| 2019-03-31 | ₹1.66 Billion | +84.05% |
| 2018-03-31 | ₹901.31 Million | -6.87% |
| 2017-03-31 | ₹967.77 Million | -- |